"Hydroxybutyrates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Salts and esters of hydroxybutyric acid.
| Descriptor ID |
D006885
|
| MeSH Number(s) |
D02.241.081.114.937 D02.241.511.429 D10.251.400.143.781
|
| Concept/Terms |
Hydroxybutyric Acids- Hydroxybutyric Acids
- Hydroxybutyric Acid Derivatives
- Acid Derivatives, Hydroxybutyric
|
Below are MeSH descriptors whose meaning is more general than "Hydroxybutyrates".
Below are MeSH descriptors whose meaning is more specific than "Hydroxybutyrates".
This graph shows the total number of publications written about "Hydroxybutyrates" by people in this website by year, and whether "Hydroxybutyrates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 0 | 2 |
| 1999 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxybutyrates" by people in Profiles.
-
Efficient Synthesis and HPLC-Based Characterization for Developing Vanadium-48-Labeled Vanadyl Acetylacetonate as a Novel Cancer Radiotracer for PET Imaging. Molecules. 2024 Feb 09; 29(4).
-
Long-Term, Prospective, Multicenter Study of Poly-4-Hydroxybutyrate Mesh (Phasix Mesh) for Hernia Repair in Cohort at Risk for Complication: 60-Month Follow-Up. J Am Coll Surg. 2022 12 01; 235(6):894-904.
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
-
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
-
A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases. FASEB J. 2020 08; 34(8):10132-10145.
-
Inhibition of porcine epidemic diarrhea virus (PEDV) replication by A77 1726 through targeting JAK and Src tyrosine kinases. Virology. 2020 12; 551:75-83.
-
Control of hyperglycemia in male mice by leflunomide: mechanisms of action. J Endocrinol. 2018 04; 237(1):43-58.
-
Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates. Cell Death Dis. 2018 03 14; 9(3):407.
-
Landscape of the regulatory elements for lysine 2-hydroxyisobutyrylation pathway. Cell Res. 2018 01; 28(1):111-125.
-
Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up. Surg Endosc. 2018 04; 32(4):1929-1936.